文档介绍：GDP方案治疗复发和难治性非霍奇金淋巴瘤的初步临床研究摘要目的:探讨GDP方案治疗复发和难治性非霍奇金淋巴瘤的临床疗效和毒副反应。方法:对复发和难治性非霍奇金淋巴瘤患者采用GDP方案(吉西他滨 1000m∥m2,第1天和第8天,柔红霉素20~30mg/mz,,地塞米松注射液40mg/天,),每3周为1个周期,连用2周期后评价疗效。疗效评定采用实体瘤评价标准。对20例患者的客观有效率(ORR)、临床获益率(CBR)、1年生存率(0S)、疾病进展时间(TTP)、不良反应发生率等指标进行分析。结果:可评价患者20例,,13例获得缓解,其中完全缓解(CR)3例,部分缓解(PR)10例,稳定(SD)5例,进展(PD)2例, 客观有效率(CR+PR)%,临床获益率(CR+PR+SD)90%。1年生存率(0S)70%,中位疾病进展时间(TTP)(4~15个月)。血浆LDH 升高的患者治疗前后相比下降显著(户=)。化疗毒副反应主要为轻度的胃肠道反应及骨髓毒副反应:白细胞和血小板下降发生率分别为75%、 30%,白细胞和血小板III、IV度毒性发生率分别为40%、5%,无明显心脏、肝肾功能损害,无治疗相关性死亡。结论:GDP方案治疗复发难治性NHL有较好的近期疗效,且大部分患者可以承受其毒性,是一个值得进一步验证的补救性化疗方案。关键词:化疗,复发和难治性非霍奇金淋巴瘤,GDP方案 The Clinical Research on theEfficacy ofGDP Regimen Oil Relapsed orRefractory Aggressive Non—Hodgkin’S Lymphoma Ab stract obj ective:To research on theclinicalefficacy and thetoxicity ofGDP regimen on relapsed orrefractory aggressive non—Hodgkin’Slymphoma. Methods:Patients with relapsed orrefractory aggressive non—Hodgkin’S Lymphoma(NHL)are taken theGDP regimen(gemcitabine 1000m掣衣on Day andDay 8,dexamethasone 40mg/day onDay 1 toDay 4,and daunorubicinum 20—30mg/m2 on Day 1 toDay 3)every threeweeks for one cycle,and itwillbe evaluated theefficacy intwo consecutive efficacy evaluation is measured using solidtumor evaluation patients are analyzed by theindicators such asORR(overall response rate),CBR(clinical beneficial rate), OS(overallsurvival),TTP(time toprogression),the adverse effects rateand SO On. Results:Of twenty assessable patients with thetreatment of , thirteen ones had response,including thatthree plete response,ten had partialresponse,five had stabledisease,andtwo had progressive overall response rate was %,the clinical beneficial rate was %, one—year overallsurvival was %,the median oftime toprogression was months(4—5months).Patients with elevation ofplasma LDH were significantly 1 pared with before and aftertreatmentQ=).The adverse effects ofChemotherapy toxicity were m